Use of Fintepla (fenfluramine), an approved oral therapy for Lennox-Gastaut syndrome (LGS), was found to safely reduce convulsive seizures in a small group of adults with hard-to-treat developmental and epileptic encephalopathy, a severe type of epilepsy that includes LGS. That’s according to a new case series from the U.K.,…
News
The U.S. Food and Drug Administration (FDA) has approved Lamlique, a ready-to-use oral liquid formulation of the antiseizure medication lamotrigine. Like other immediate-release lamotrigine products, Lamlique is indicated for use as an add-on treatment to help control seizures in people ages 2 and older who have Lennox-Gastaut syndrome…
Vagus nerve stimulation (VNS), a treatment that uses a small, implanted device to deliver electrical signals to the vagus nerve, was linked to fewer seizures in many children with Lennox-Gastaut syndrome (LGS), with the benefits generally becoming clearer over time, a review study…
Caregivers of people with Lennox-Gastaut syndrome (LGS) in focus groups most frequently cited knowledge gaps on the part of physicians as a barrier to accessing care and information. Access to care, access to information, care coordination, and transitioning from pediatric to adult care were key concerns for the group…
A checklist based on international diagnostic criteria, developed by specialists in Europe, may help doctors identify Lennox-Gastaut syndrome (LGS) earlier and support further evaluation when a diagnosis is unclear, a study showed. Because some characteristic features of LGS may emerge only…
People who meet the clinical criteria for Lennox-Gastaut syndrome (LGS) may have substantial differences in their seizure patterns, brain activity, and developmental impairment, and some severely affected patients may not meet all formal electroencephalogram (EEG) criteria used to define the condition, a study suggested. Among 105 people with clinically defined…
Questionnaires used in research to assess behavior, communication, and quality of life in people with Lennox-Gastaut syndrome (LGS) may not always capture the concerns that matter most to patients and their families, a study found. In focus groups involving caregivers, clinicians, and advocates, participants identified several areas they felt…
Fintepla (fenfluramine) can rapidly reduce seizure frequency in people with Lennox–Gastaut syndrome (LGS), with the greatest benefits typically appearing after a few months of treatment and common side effects often becoming less noticeable over time, according to a post hoc analysis of Phase 3 clinical data. “Patients, parents,…
Children with Lennox-Gastaut syndrome (LGS) experience substantial sleep disruptions, which caregivers can track at home with an electroencephalogram (EEG) headband, a study found. The HEADFIRST study showed that the Waveband device, which uses four sensors placed over the front and back of the head to record the brain’s…
Two nerve-stimulating devices, vagus nerve stimulation (VNS) and deep brain stimulation (DBS), were associated with similar reductions in seizure frequency over two years in people with Lennox-Gastaut syndrome (LGS), according to a Mayo Clinic study. At two years, however, combined DBS and ongoing VNS was associated with greater seizure…
Recent Posts
- Approved LGS therapy may safely reduce convulsive seizures in adults
- FDA approves new ready-to-use liquid treatment for LGS, other seizures
- Raising a child with LGS made me appreciate the kindness of strangers
- LGS girls’ 1st period doesn’t change seizure frequency, study finds
- Vagus nerve stimulation reduces seizures in kids with LGS